Bayer AG NABAYN
▲ PositiveDemandrelevance
Bayer expands its Canadian distribution partnership with Mint to cover a broader range of Bayer medicines including XARELTO and women's health products, extending product reach.
Impact on assets 1
Health Care
Bayer AG NATheme Impact 1
Off-coverage companies 1
Mint Pharmaceuticals Inc.Private± Mixed
relevance
Related news
United StatesJohnson & Johnson Expected to Post Higher Earnings and Revenue for September Quarter
Johnson & Johnson is expected to report quarterly earnings of $2.90 per share and revenues of $25.37 billion when it releases results for the quarter ended September 2026 on October 13, according to the Zacks Consensus Estimate. The EPS figure represents a year-over-year increase of 3.6%, while revenue is expected to rise 5.8% from the year-ago quarter. The consensus EPS estimate has been revised 0.21% lower over the last 30 days, and the Most Accurate Estimate sits below the Zacks Consensus Estimate, producing an Earnings ESP of -0.01%. The stock currently carries a Zacks Rank of #3, a combination that makes it difficult to conclusively predict an earnings beat. In the last reported quarter, Johnson & Johnson posted earnings of $2.90 per share against an expectation of $2.84, a surprise of +2.11%, and the company has beaten consensus EPS estimates in each of the last four quarters.
About megatrends
Aging Population › Chronic-Disease Pharma Franchises Demand
JNJ · Capital · Positive J&J is expected to post higher year-over-year EPS ($2.90, +3.6%) and revenue ($25.37B, +5.8%) for the September quarter.
DenmarkNovo Nordisk Rated Zacks Rank #3 as Earnings Estimates Rise
Novo Nordisk is rated Zacks Rank #3 (Hold), with the Zacks Consensus Estimate for the current quarter rising 6.9% over the last 30 days to $0.80 per share, a year-over-year change of -21.6%. For the current fiscal year, the consensus earnings estimate of $3.53 points to a change of -10.9% from the prior year and has moved +2.4% over the last 30 days, while the next fiscal year's estimate of $3.41 indicates a -3.5% change and has slipped -0.3% over the past month. Consensus sales estimates stand at $11.41 billion for the current quarter, $46.1 billion for the current fiscal year and $47.16 billion for the next fiscal year, indicating changes of -2.8%, -1.5% and +2.3%, respectively. In the last reported quarter, Novo Nordisk posted revenues of $12.21 billion, up 4.5% year over year and an 8.34% surprise over the Zacks Consensus Estimate of $11.27 billion, with EPS of $0.96 versus $0.97 a year ago and a +17.07% EPS surprise. The stock is graded A on the Zacks Value Style Score, indicating it trades at a discount to its peers, though its Zacks Rank #3 suggests it may perform in line with the broader market near term.
About megatrends
Aging Population › Chronic-Disease Pharma Franchises Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital
Longevity & Life Extension › GLP-1 Healthspan Proxies Capital
NVO · Capital · Neutral Zacks Rank #3 (Hold) with consensus earnings estimates rising 6.9% for the current quarter but still down year over year, an analyst-valuation update.
DenmarkUnited States▼
Novo Nordisk Targets Over $23 Billion in Pipeline Sales by 2035 as GLP-1 Competition Bites
Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
Aging Population › Chronic-Disease Pharma Franchises ▼Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▼Competition
NVO · Competition · Negative Novo Nordisk has lost ground to rival Lilly in the injectable GLP-1 market and faces semaglutide patent expirations, prompting a Morgan Stanley downgrade.
LLY · Competition · Positive Novo Nordisk acknowledged losing ground to rival Lilly in the injectable GLP-1 market, a competitive gain for Lilly.
ABSI · Demand · Positive Absci shares rose after Novo Nordisk's strategy presentation highlighted the hair-loss market, signaling potential demand for hair-loss drug developers.
MANE · Demand · Positive Veradermics shares rose after Novo Nordisk's strategy presentation signaled interest in the hair-loss market, a potential demand driver for hair-loss drug developers.
United StatesTrump Administration Picks 10 Drugmakers for New 340B Rebate Pilot
The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.
About megatrends
Aging Population › Chronic-Disease Pharma Franchises Regulation
4503.JP · Regulation · Positive Astellas is one of the selected manufacturers participating in the 340B rebate pilot program.
ABBV · Regulation · Positive AbbVie is one of 10 selected manufacturers in the new 340B rebate pilot, allowing it to pay rebates after purchase rather than upfront discounts.
AMGN · Regulation · Positive Amgen is selected for the 340B Rebate Model Pilot, shifting it to a post-purchase rebate model for discounted drugs.
AZN.LSE · Regulation · Positive AstraZeneca is selected for the 340B rebate pilot, letting it verify and pay rebates rather than give upfront discounts.
BMY · Regulation · Positive Bristol Myers is among the 10 drugmakers chosen for the administration's 340B rebate pilot taking effect January 1.
GSK.LSE · Regulation · Positive GSK is named among the 10 drugmakers in the new 340B rebate model pilot taking effect January 1.
United States▲4
AbbVie Wins FDA Approval for Juvmo, First Selective D1/D5 Parkinson's Pill
AbbVie has secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease, with a commercial launch targeted for October 2026. Juvmo is the first selective D1/D5 dopamine receptor agonist that can be used both as a standalone treatment and in combination with levodopa, the current standard of care for Parkinson's symptoms. The approval expands AbbVie's Parkinson's portfolio, which already includes Vyalev and Duopa, and management expects the three therapies to collectively represent a peak-sales opportunity of more than $5 billion. Neuroscience now accounts for nearly a fifth of AbbVie's overall topline and generated $6.1 billion in revenues in the first half of 2026, up 22% year over year, with the company expecting approximately $12.7 billion in neuroscience revenues for the full year. The approval could also deliver a commercial payoff from AbbVie's approximately $8.7 billion acquisition of Cerevel Therapeutics in 2024, a deal that came under pressure after emraclidine failed in two registration-enabling phase II studies in schizophrenia and prompted a $3.5 billion impairment charge. AbbVie competes in neuroscience with Biogen, which markets Leqembi with Eisai and Zurzuvae, and Johnson & Johnson, whose portfolio is anchored by Spravato and Invega Sustenna and was strengthened by last year's acquisition of Intra-Cellular Therapies, adding Caplyta.
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Technology
Aging Population › Chronic-Disease Pharma Franchises ▲Technology
ABBV · Regulation · Positive FDA approval of Juvmo, a first-in-class selective D1/D5 Parkinson's pill, expands AbbVie's neuroscience portfolio toward a >$5B peak-sales opportunity.
United States▲
AbbVie Draws Investor Attention as Zacks Flags Consensus Estimates
AbbVie has landed on Zacks.com's list of the most searched stocks, drawing fresh attention to the drugmaker's near-term outlook. For the current quarter, AbbVie is expected to post earnings of $3.85 per share, a change of +107% from the year-ago quarter, while the Zacks Consensus Estimate has moved -0.1% over the last 30 days. The consensus earnings estimate of $14.05 for the current fiscal year indicates a year-over-year change of +40.5%, and the next fiscal year's consensus of $16.12 points to a change of +14.8%. On the top line, the consensus sales estimate for the current quarter of $17.36 billion indicates a year-over-year change of +10%, with current and next fiscal year estimates of $67.56 billion and $73.39 billion indicating changes of +10.5% and +8.6%. In the last reported quarter, AbbVie posted revenues of $16.99 billion, up +10.2% year over year, and EPS of $3.65 versus $2.97 a year ago, beating the Zacks Consensus Estimate of $16.81 billion by +1.07% on revenue with an EPS surprise of +0.27%. The recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie, and the stock is graded C on the Zacks Value Style Score.
About megatrends
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Capital
ABBV · Capital · Neutral AbbVie is the subject, drawing attention on Zacks' most-searched list with consensus estimates and a Zacks Rank #3 (Hold), a neutral analyst/valuation update.